Vimarsana
Biggest News Aggregation in the World

Page 3 - Jonathan Graham News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jonathan Graham. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jonathan Graham Today - Breaking & Trending Today

Fostering North Yorkshire in Sand Hutton conference - Vimarsana News

Fostering North Yorkshire in Sand Hutton conference

More than 60 foster carers came together at Fostering North Yorkshire’s conference at Sand Hutton to be thanked for their support and honoured for…

Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria - Vimarsana News

Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria

There is currently no evidence-based treatment for the smallest babies with malaria The CALINA study tested a new ratio and dose of Coartem® to account for metabolic differences in babies under 5...

Novartis and Medicines for Malaria Venture announce - Vimarsana News

Novartis and Medicines for Malaria Venture announce

There is currently no evidence-based treatment for the smallest babies with malaria The CALINA study tested a new ratio and dose of Coartem® (artemether-...

Novartis radioligand therapy Lutathera&#xAE; FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors - Vimarsana News

Novartis radioligand therapy Lutathera&#xAE; FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors

Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric and adult patients Gastroenteropancreatic neuroendocrine...

Novartis radioligand therapy Lutathera&#xAE; FDA approved as - Vimarsana News

Novartis radioligand therapy Lutathera&#xAE; FDA approved as

Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17)...